Endometriosis is one of medicine’s most stubborn puzzles: a hormone-dependent, chronic inflammatory disease in which tissue resembling the uterine lining takes root outside the womb, plastering itself onto the ovaries, peritoneum and other pelvic surfaces, where it bleeds cyclically, scars, forms adhesions and hurts — and, in many cases, destroys fertility. A sweeping synthesis of molecular research, published in Reproductive Sciences by Mengmeng Kuai, Baohua Li and colleagues at Jiangsu University in China, now maps the disease’s inner circuitry in unprecedented detail, from runaway local estrogen production and progesterone resistance to saboteur immune cells and a dozen self-reinforcing signaling cascades. The review’s central message is sobering and hopeful at once: the very molecular alterations that make endometriosis so insidious could, if harnessed, finally deliver what patients have lacked for generations — a reliable test that catches the disease early, and treatments that go beyond hormonal shutdown and repeat surgery.

The clinical stakes are enormous. Because symptoms — debilitating pelvic pain, painful periods, pain during intercourse and infertility — overlap with other pelvic disorders, and because no biomarker is approved for definitive early detection, diagnosis typically rests on laparoscopic visualization with histological confirmation, while ultrasound and magnetic resonance imaging mainly serve to identify deep infiltrating disease. The authors emphasize that the lack of reliable early detection biomarkers significantly contributes to diagnostic delays that can stretch across years. Current guidance, including the 2022 European Society of Human Reproduction and Embryology guideline discussed in the paper, still anchors diagnosis to surgical confirmation. The most widely used marker, CA-125 — a glycoprotein better known from ovarian cancer monitoring — rises in endometriosis but lacks the sensitivity and specificity needed to catch minimal or mild disease, precisely the stages at which early intervention could alter a patient’s trajectory. Even semi-invasive proposals, such as measuring the density of small sensory nerve fibers in endometrial biopsies, have not entered routine practice.

The review traces the disease’s origins to a two-hit logic. The dominant theory, retrograde menstruation, holds that menstrual debris flows backward through the fallopian tubes into the peritoneal cavity; recent DNA evidence, highlighted in the review, now lends this origin strong support. Yet reflux is nearly universal among menstruating women, so lesion establishment demands a permissive molecular terrain: displaced cells must adhere to peritoneal surfaces, invade through the extracellular matrix, survive immune surveillance and secure a blood supply. Matrix metalloproteinases, enzymes that digest the tissue scaffold, are central to this invasion — in a classic experiment cited by the authors, suppressing these enzymes blocked the establishment of ectopic lesions by human endometrium transplanted into mice. Endometrial stem and progenitor cells may seed early-onset disease, while downregulation of the cell-cycle brake p27Kip1 and failure to properly modulate adhesion molecules such as E-cadherin and β-catenin during the implantation window mark the endometrium of affected women.

Hormonally, the disease behaves as an estrogen self-amplifier. Ectopic lesions express aromatase cytochrome P450, the enzyme that synthesizes estradiol locally — an enzyme normally absent from the uterine lining. A second defect compounds the first: endometriotic stromal cells fail to produce the paracrine factors that induce 17β-hydroxysteroid dehydrogenase type 2 and its transcriptional regulator Sp1, the machinery that normally inactivates estradiol by converting it into estrone. Local production plus impaired degradation creates a vicious estrogenic loop. Estrogen receptor β dominates the lesion landscape, while membrane GPR30 signaling can activate steroidogenic factor-1 to drive proliferation further, and REA, a repressor of estrogen receptor activity that restrains lesion progression, is compromised. Downstream, estrogen-responsive genes such as GREB1, c-MYC and cyclin D1 surge, and a recently described feed-forward loop between GREB1 and steroid receptors governs the abnormal endometrial function that underpins both lesion growth and fertility failure.

Progesterone, which should counterbalance estrogen and quieten the endometrium each cycle, loses its grip — the phenomenon of progesterone resistance. The review catalogs the mechanisms: altered ratios of progesterone receptor isoforms A and B, whose balanced actions normally regulate ovulatory transcription through RUNX factors and chromatin remodeling and suppress uterine contractility via the Oxtr–Plcl2–Trpc3 pathway; loss of MIG-6, which unleashes ERBB2-driven resistance; decreased FOXA2 expression that promotes proliferation and migration; and heme, abundant in degraded blood pooled within lesions, which reshapes cellular programs into a progesterone-resistant profile. Heightened AKT and MEK1/2 kinase activity further mislocalizes progesterone receptors. The clinical consequence is stark: progestins — the backbone of medical therapy, including the synthetic progestin dienogest, which down-regulates aromatase and inflammatory and neuroangiogenesis factors through both receptor isoforms — often blunt symptoms without reversing the underlying molecular state. Progesterone resistance also explains why hormonal suppressives fail to fully normalize the eutopic endometrium where embryos must implant, leaving poor responders with few options.

Equally decisive is the immune system’s inversion. Instead of clearing displaced endometrial cells, the peritoneal environment recruits, reprograms and protects them. Macrophages accumulate under the influence of macrophage colony-stimulating factor and flood the cavity with interleukin-6 and tumor necrosis factor-α, mediators that spur the proliferation of ectopic and even eutopic endometrial cells. Pyroptotic T cells release active interleukin-16, which drives ovarian endometriosis development. Natural killer cells, the first line of defense against aberrant cells, are disarmed — soluble MICA shed into peritoneal fluid impairs their degranulation and effector functions — while CD8+ T cells, prompted by endometriotic stromal cells, lose cytotoxic competence. Regulatory T cells, meanwhile, cooperate with proinflammatory cytokines to foster angiogenesis and are steered by stromal chemokines such as TECK to promote lesion growth and invasion. Exosomes shed from the uterine cavity extend this immune dysregulation by inhibiting the JNK signaling pathway. The interleukin-33/ST2 axis adds another layer, promoting epithelial-mesenchymal transition through β-catenin phosphorylation while, via macrophages, blocking ferroptosis of stromal cells through the ATF3/SLC7A11 axis.

Beneath these processes churns oxidative chaos. Reactive oxygen species activate NF-κB, the master inflammatory switch, and advanced oxidative protein products accumulate in patient fluids in proportion to disease stage. Iron released from degraded blood overwhelms the follicular microenvironment through ROS/HIF-1α signaling, and endometrial stromal cells undergo ferroptosis — an iron-catalyzed, lipid-peroxidation-driven form of cell death — which paradoxically fuels angiogenesis around lesions. Hypoxia hinders methylation of the prostaglandin synthase gene PTGIS in stromal cells, steering natural killer cells toward a CD16-negative state that tolerates the lesions. Extracellular succinate from the ectopic milieu drives adhesion and implantation growth through its receptor SUCNR1. The ovaries are not spared: endometriotic inflammation triggers excessive activation of primordial follicles through the PI3K–PTEN–AKT–FOXO3 pathway, while follicular fluid progesterone suppresses HPGD and COX2 in granulosa cells via NF-κB, compromising follicular development. Overarching signaling networks knit these insults together: Wnt/β-catenin activation, PI3K/AKT/mTOR signaling, genome-wide genetic evidence implicating MAPK pathways, hypoxia-triggered nuclear translocation of the Hippo pathway effector YAP1, TGF-β-driven invasion through ERK/MAPK, and autophagy hijacked through transcription factor EB. Nerve growth factor in peritoneal fluid sprouts neurites into lesions, helping wire the disease’s signature chronic pain.

It is precisely this molecular noise that the biomarker hunt hopes to convert into signal. The review surveys an expansive toolkit: vascular endothelial growth factor A, matrix metalloproteinase-9, survivin, monocyte chemoattractant protein-1, interleukin-6 and interleukin-17 in serum and peritoneal fluid; the transcriptional and epigenetic regulators BCL6 and SIRT1; microRNAs such as miR-200c, miR-34a-5p, miR-17 and miR-375-3p, with salivary miR-135a and commercial saliva tests such as Endotest already entering cost-effectiveness debates; and menstrual blood, in which aromatase, SF-1, HSD17B2 and osteopontin can be detected noninvasively. Metabolomics has flagged phosphatidic acid, phosphatidylcholine and phosphatidylserine as early-stage discriminators, proteomics has surfaced cartilage oligomeric matrix protein and TGFBI, and plasma protein panels combined with statistical models now approach clinically meaningful diagnostic performance. Urinary peptide profiles, circulating endometrial cells and even the gut microbiome — which outperformed cervical microbiota for early diagnosis in one cited study — extend the search. Imaging is converging on the same goal: molecular imaging with desorption electrospray ionization mass spectrometry can map lipid signatures directly within tissue, and steroid-conjugated magnetic resonance probes designed to highlight progesterone receptor-expressing organs hint at lesion-specific contrast. The authors stress that single markers will not suffice: multi-marker panels interpreted through machine learning, and validated against rigorous prospective designs, are the realistic path forward.

On the therapeutic front, the review charts a move from brute-force hormonal suppression toward precision interventions. Alongside refinements of endocrine strategy — aromatase inhibitors, dual inhibitors of steroid sulfatase and 17β-hydroxysteroid dehydrogenase type 1, and estetrol, which curbed disease development in a murine model — a wave of non-hormonal candidates is advancing in preclinical studies: antagonists of the neuropeptide S receptor, a validated nonhormonal target; blockade of the prostaglandin receptors EP2 and EP4; an anti-interleukin-6 receptor antibody; macrophage migration inhibitory factor antagonists that blocked lesion development in vivo; TET3 targeting in macrophages; the innate immune regulator NLRC5, which restrains estrogen receptor β-driven inflammation; sphingosine-1-phosphate receptor 3 against fibrosis; the epigenetic regulator EZH2; and prolactin receptor antibodies aimed at pain. Natural compounds add breadth — melatonin disrupting mitochondrial function and EGFR phosphorylation, alongside curcumin, resveratrol, fraxetin, thymol, crocin and β-elemene, the last of which induces ferroptosis through MAPK and STAT3 signaling — though poor bioavailability still demands advanced delivery systems such as nanoparticle formulations.

The authors are candid about the distance between bench and bedside: mechanistic discoveries have yet to translate into approved diagnostics or drugs at the pace patients need. But their synthesis suggests a coherent strategy. Molecular classification could stratify patients by pathway activity rather than surgical stage alone; multi-biomarker panels could catch disease before lesions proliferate; and combinations of anti-inflammatory, anti-proliferative and pro-apoptotic agents could be paired with minimal hormonal exposure. If preclinical momentum holds, addressing diagnostic delays and advancing innovative therapies may yield genuinely targeted management for a disease long managed by trial and error. For the millions living with endometriosis, the molecular map is finally detailed enough to be actionable — and the race to turn it into blood tests and non-hormonal medicines is now unmistakably underway.

Subject of Research: Molecular mechanisms of endometriosis — sex hormone regulation, endometrial microenvironment, immune dysregulation and signaling pathways — for early diagnostic biomarker discovery and therapeutic target identification

Subject of Research: Medicine

Article Title: Molecular Insights Into Endometriosis for Early Detection and Therapeutic Targets

Article References: Kuai, M., Li, B., Shi, Z., Huang, Q., Pan, Y., Tang, M., Gao, X., Fang, J., & Lü, P. (2026). Molecular Insights Into Endometriosis for Early Detection and Therapeutic Targets. Reproductive Sciences, 33(7), 1228-1248. https://doi.org/10.1007/s43032-026-02124-5

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02124-5

Keywords: Endometriosis, Molecular mechanisms, Early diagnosis, Biomarkers, Therapeutic targets, Estrogen signaling, Progesterone resistance, Immune dysregulation, Inflammation, Signaling pathways, Non-hormonal therapy, Biomarker panels

Cite Scienmag News
APA MLA Chicago

Ophelia Keating. (August 31, 2026). Molecular Clues to Endometriosis Offer Early Detection and New Treatment Targets. Scienmag. https://scienmag.com/molecular-clues-to-endometriosis-offer-early-detection-and-new-treatment-targets/

Copy citation Download RIS

Tags: advances in molecular research for endometriosischallenges in diagnosing endometriosischronic pelvic pain and infertility in endometriosisearly detection biomarkers for endometriosisendometriosis molecular mechanismsestrogen production and progesterone resistancegenetic and epigenetic factors in endometriosishormone-dependent inflammatory diseasehormone-dependent inflammatory diseasesimmune cell involvement in endometriosislocal estrogen production in endometriosismolecular signaling pathways in endometriosismolecular targets for endometriosis treatmentnon-invasive diagnostic methods for endometriosisnovel therapeutic approaches for endometriosispotential non-invasive diagnostic testsprogesterone resistance in endometrial tissuesignaling pathways in endometriosis developmentsurgical and imaging diagnostics for endometriosissurgical diagnosis and imaging techniquestreatment targets beyond hormonal therapy